Myriad Genetics (MYGN) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.76 --0%
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
RCBC, SSL, PFBC, More
Financial Fact:
Companion diagnostic services: 12.4M
Today's EPS Names:
RCBC, SSL, PFBC, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.
Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015 revenue of $750-770 million, versus the consensus of $758.3 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Investar Holding (ISTR) Tops Q3 EPS by 1c
- Burke & Herbert Bank & Trust Company (BHRB) Tops Q3 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
